However, since the biological actions of ZAG have not been fully characterized, it is important to study the effects of diabetic treatment, especially new anti-diabetic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, on the plasma levels of ZAG in T2DM patients. This evidence concerns the gene AZGP1 and type 2 diabetes mellitus.